<DOC>
	<DOC>NCT01992211</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetic Profile and Safety/Tolerability of BCWP_C003 compared to Co-Administration of Crestor 10mg and Glucophage XR 1000mg, and to evaluate the food effect of Pharmacokinetic profile of BCWP_C003 after administration.</brief_summary>
	<brief_title>Evaluating of Pharmacokinetic Profile of BCWP_C003 and Co-administration of Rosuvastatin and Metformin</brief_title>
	<detailed_description>Clinical Trials to Evaluate the Pharmacokinetic Profiles and Safety/Tolerability of BCWP_C003 Formulation compared to Coadministration of Rosuvastatin and Metformin SR Formulation, and to Evaluate the Effect of Food on the Pharmacokinetic Profile of BCWP_C003 after Single Oral Administration to Healthy Male Subjects.</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Healthy Male Volunteer, age 19 to 45 years at the time of screening Body weight is not less than 55kg, not more than 90kg and the result of Body Mass Index(BMI) is not less than 18.5, not more than 25.0 Subject who has no congenital, chronic disease, and no disease symptom or finding in medical examination result Subject who comprehended the purpose, contents of the study, property of clinical drug and signed the informed consent to participate in the trial having the willingness Subject who has history of hypersensitivity reaction for relevant drug(statin, biguanide) or clinically significant hypersensitivity reaction Subject who has history or presence of clinically disease in liver, kidney, gastrointestinal tract, respiratory system, musculoskeletal, endocrine system, mental disorder, bloodtumor, cardiovascular. Particulary, subject who has bleeding disorder or tend to be bleeding with bruised easily Subject who has family history of hereditary muscular disorder or muscular side effect Subject who has history of gastrointestinal tract disorder which can affect the drug absorption or surgery(excluding appendectomy, hernia surgery) Subject who had taken diagnosis with peptic ulcer within 2 month prior to the drug administration Subject who has results of clinical laboratory test as follows : AST, ALT level exceed the normal range more than 1.5 times Total bilirubin level exceed the normal range more than 1.5 times Creatinine clearance under 60mL/min calculated by MDRD In the vital sign, systolic blood pressure is more than 150mmHg, less than 90mmHg or diastolic blood pressure is more than 95mmHg, less than 50mmHg Subject who has presence or history of drug abuse, or positive screening for drug abuse â†’ Alcohol abuse defines to drink over 21 unit/week(alcohol 1unit = 10g = 12.5 mL) persistingly Subject who participated in another clinical trial within 3 month prior to the drug administration Subject who had taken medicine(Barbital etc) related drug metabolizing enzyme induction or inhibition within 1 month prior to the drug administration Subject who had taken prescription drug or oriental medicine within 2 weeks or OTC drug or vitamin formulation within a week prior to the drug administration Subject who had a diet which can affect the absorption, distribution, metabolism or elimination of Rosuvastatin/Metformin (Particulary, Grapefruit within 48h prior to the drug administration) Subject who donated whole blood within 2 month or component blood within 1 month prior to the drug administration Subject who smokes more than 10 cigarettes per day Subject who has positive HBsAg, HCV Ab or HIV Ab Subject who is judged to be ineligible by principal investigator or subinvestigator according to various test results</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>